key: cord-0766315-mn4pot5k
authors: Liu, Yalin; Luo, Xianghang
title: New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
date: 2022-02-28
journal: Front Med
DOI: 10.1007/s11684-021-0873-2
sha: 51da0fd1af60e3bd8dd1b74494b2e1ee08fc8c44
doc_id: 766315
cord_uid: mn4pot5k

Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.

With the improvement of people's living standards in recent years, diabetes has become an important factor threatening human health. The International Diabetes Federation statistics in 2019 showed that approximately 463 million adults aged 20-79 years in the world were suffering from diabetes, indicating that 1 in 11 people had diabetes. Another estimate is that the number of diabetic patients will reach 578.4 million by 2030, and the number may reach 700.2 million by 2045 [1] . Diabetes is a kind of metabolic disease characterized by high blood sugar and is often characterized by polydipsia, polyphagia, polyuria, and weight loss. Moreover, long-term hyperglycemia causes chronic damage and dysfunction of various tissues, especially eyes [2] , kidneys [3] , heart [4] , blood vessels [5] , and nerves [6] . Meanwhile, obesity is a chronic disease that requires long-term treatment [7, 8] , and approximately 650 million people suffer from obesity worldwide [9] . Obesity is a recognized risk factor for ischemic heart disease, atherosclerosis, and stroke [10] . Furthermore, it can lead to common chronic diseases such as chronic kidney disease, hypertension, and type-2 diabetes (T2D) [11] . Nowadays, a range of restrictive measures limiting the spread of coronavirus disease 2019 (COVID-19) may have a negative impact on weight-management practices, and a high body mass index has also been identified as a risk factor for COVID-19 mortality [12] [13] [14] .

Obesity and T2D are closely correlated. People with abnormal glucose metabolism often have dyslipidemia, hypertension, hyperuricemia, fatty liver, and obesity, and insulin resistance is the common cause of these abnormalities. Obesity is regarded as an important cause of T2D. As the condition progresses, many obese patients are bound to evolve to the stage of clinical T2D, and a series of complications will soon occur. Therefore, the development of efficient weight-loss drugs is imminent. However, no perfect drug choice exists for obesity. Complex medication regimens [15, 16] and subsequent adverse events may further affect patient compliance.

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone secreted by the L cells of the small intestine after eating stimulation [17] . GLP-1 receptors are primarily distributed in the pancreas, intestine, and central nervous system. GLP-1 receptor agonists can enhance insulin secretion caused by increased glucose and inhibit glucagon secretion. In detail, glucose plays a major role in regulating insulin secretion. When extracellular glucose levels rise, pancreatic β cells allow glucose entry via glucose transporter-2 [18]. This phenomenon elevates intracellular ATP [19, 20] , thereby promoting the closure of ATPsensitive potassium channels [21] . Furthermore, changes in cell-membrane potential and voltage-dependent Ca 2+ channel activation lead to Ca 2+ flowing in from outside the cell, which then promotes exocytosis and insulin secretion. GLP-1-mediated insulin secretion can be observed only at elevated glucose concentration. GLP-1 analogs produce more cAMP by binding to GLP-1 receptor on pancreatic β cells [19] and subsequently enhance glucose activity by further increasing the permeability of Ca 2+ channels, thereby enabling more Ca 2+ influx to increase insulin release [22] . It can also delay stomach emptying [23] and suppress appetite [24] ( Fig. 1 ; created using material in Servier Medical Art under CC BY 3.0 license). Some GLP-1 receptor agonists such as liraglutide, exenatide, and efpeglenatide [25] have been marketed and used to treat obese patients, and their efficacy is shown in Table 1 . Furthermore, GLP-1 receptor agonist such as liraglutide provides better and longer glycemic control with a lower risk of hypoglycemia in individualized treatment of T2D patients. It showed as well an advantage in reducing major cardiovascular adverse events and mortality compared with other treatment regimens [26] . In general, GLP-1 receptor agonists are extensively used in the treatment of obesity and T2D. However, their efficacy and usage mode can still be improved. Semaglutide is a kind of human GLP-1 analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. Notably, the risk of hypoglycemia is not high [27] .

Clinical evidence of the effect of subcutaneous semaglutide on T2D

T2D is a complex disease with different factors affecting blood-sugar control. Many people still cannot reach the recommended blood-glucose concentration [28] despite wide-ranging treatment options [15] . Moreover, complex medication regimens [15, 16] , subsequent adverse events, medication-induced weight gain, and possible risk of hypoglycemia [29] may affect patient compliance and further hinder the achievement of blood-glucose goals. Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) is a series of phase-3 clinical trials that comprehensively evaluate the efficacy, safety, cardiovascular, and renal adverse events, as well as other outcomes, of subcutaneous semaglutide in the T2D population.

Among them, SUSTAIN 1-5 [30-34] and SUSTAIN 7-10 [35-38] compare semaglutide with placebo and active control drugs in a randomized and double-blind trial population, with the efficacy and safety of semaglutide as the main research endpoints. The results after 30-56 weeks show that semaglutide performs significantly better in reducing HbA 1c than other controls, including placebo, sitagliptin, insulin glargine, canagliflozin, dulaglutide, liraglutide, and exenatide extended release. The proportion of patients with HbA 1c < 7% or ≤ 6.5% in the semaglutide group is significantly higher than that in the other controls. As high as 80% of patients in the semaglutide 1.0 mg group could achieve the standard rate of HbA 1c (HbA 1c < 7%), with the highest reaching 1.8%. Additionally, the weight-loss effect of semaglutide is better than those of the others, with the semaglutide 1.0 mg group losing weight up to 6.5 kg. In terms of safety, semaglutide has a similar incidence rate of adverse events to other controls, among which the most common adverse events Fig. 1 Regulatory mechanism of semaglutide. Semagluide is a good choice for weight loss, and its once-a-week dosing method greatly improves compliance. However, compared with oral administration, injection administration still has certain operational difficulties. In that case, the dosage form of semaglutide and the corresponding weight-loss effect can further be explored in the future. Other GLP-1 receptor agonists such as liraglutide also have weight-loss effects [50] (Table 1) , but these are not as obvious as those of semaglutide. Among them, liraglutide needs to be subcutaneously administered once a day, and these GLP-1 receptor agonists can lead to weight loss of only up to 7.3 kg, whereas semaglutide 2.4 mg can lead to an average weight loss of 15 kg. However, due to different research objects and different experimental designs, the exact corresponding effects compared with semaglutide are not easy to obtain. Thus, trials can also be designed to compare the weight-loss effects of semaglutide and other weight-losing products.

Lifestyle intervention is not clearly defined in the study of Wilding et al. [49] , and it has a considerable influence on weight loss [51, 52] . From this point of view, whether the results of complementary lifestyle interventions exaggerate the effects of semaglutide remains to be discussed. Furthermore, whether weight rebound occurs after semaglutide withdrawal, resulting in significant weight gain or drug dependence, can also be studied. Notably, the methodology of studies evaluating gastrointestinal symptoms is primarily through self-report rather than the use of available validated gastrointestinal symptom questionnaires.

Obesity is a significant risk factor for cardiovascular disease and related complications that significantly increase the risk of death [53, 54] . Individuals with abdominal obesity are at increased risk of angina, heart failure, myocardial infarction, and atrial fibrillation [55] . As an auxiliary means of lifestyle intervention, the use of antiobesity medications can improve the risk factors of cardiovascular disease [56, 57] and usually exert a beneficial effect on certain cardiometabolic parameters [58] . Studies have shown that the children of mothers exposed to metformin have lower central hemodynamics and diastolic index than those exposed to placebo. These results suggest that the use of metformin in obese pregnant women may have beneficial cardiovascular effects on their offspring [59] . However, some reports have reflected poor cardiovascular outcomes after the application of weightloss drugs [60, 61] . Aminorex can result in pulmonary hypertension; fenfluramine and dexfenfluramine may result in cardiac valvulopathy; and sibutramine may lead to myocardial infarction. After the withdrawal of sibutramine from the market due to its life-threatening side effects, the FDA sought for cardiovascular safety data on new antiobesity medications [62] . Therefore, continuous monitoring of antiobesity products for any potential safety issue is important [63] . Nevertheless, a once-a-week subcutaneous injection of semaglutide 2.4 mg is still proven to play a crucial role in improving the condition of obese or overweight people, with only mild to moderate gastrointestinal adverse reactions. Overall, semaglutide has great potential and value in various diseases and may benefit many more patients in the near future through a few more studies in obese or overweight people.

Obesity is closely correlated with T2D, which brings about many complications. Semaglutide is a kind of human GLP-1 analog that has undergone a series of clinical trials for obesity and T2D treatment. However, its effects on cardiovascular disease when treating obese people require further study.

Yalin Liu and Xianghang Luo declare that they have no conflict of interest. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee. Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. Obesity (Silver Spring) 2020; 28 (9) 

Diabetes Atlas IDF

Mechanisms behind retinal ganglion cell loss in diabetes and therapeutic approach

Hypoxia and hypoxia-inducible factors in diabetes and its complications

Cardiorespiratory fitness in patients with type 2 diabetes: a missing piece of the puzzle

The link between diabetes and atherosclerosis

Alzheimer's disease and diabetes: insulin signaling as the bridge linking two pathologies

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity

Obesity Management Task Force of the European Association for the Study of Obesity. European guidelines for obesity management in adults

World Health Organization. Obesity and overweight

Is there a place for dietary fiber supplements in weight management?

PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes

E; PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial

Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial

PIONEER 7 investigators. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, openlabel, randomised, phase 3a trial

PIONEER 8 Investigators. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

PIONEER 10 Investigators. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Once-weekly semaglutide in adults with overweight or obesity

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, doubleblind, placebo-controlled trial

Effects of 4-and 6-h timerestricted feeding on weight and cardiometabolic health: a randomized controlled trial in adults with obesity

Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome

Cardiovascular imaging in obesity

Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism

Metabolically healthy obesity and the risk of cardiovascular disease in the general population-analysis of a nationwide epidemiological database

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects

The risk of cardiovascular complications with current obesity drugs

Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring

FDA withdrawal of fen-phen

FDA announces sibutramine has been withdrawn from the market

The FDA's assessment of two drugs for chronic weight management

Anti-obesity drugs: past, present and future

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study